HRT Financial’s Clarus Therapeutics Holdings, Inc. Warrants CRXTW Stock Holding History

HRT Financial’s Portfolio CRXTW Stock Details CRXTW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-39,758	Closed	-$3K	–	3844
2022 Q2	$3K	Sell	39,758 -6,699	-14%	-$659	﹤0.01%	2795
2022 Q1	$6K	Hold	46,457	–	–	﹤0.01%	2951
2021 Q4	$13K	Hold	46,457	–	–	﹤0.01%	3005
2021 Q3	$34K	Buy	46,457 +14,224	+44%	+$10.7K	﹤0.01%	3098
2021 Q2	$24K	Buy	+32,233	New	+$20.2K	﹤0.01%	2717

Other funds holding CRXTW

MSU

Mizuho Securities USA New York $6.2B AUM 35.46% 1-Year Est. Return

HRT Financial's CRXTW Position: Q3 2022 in Review

HRT Financial sold out of Clarus Therapeutics Holdings, Inc. Warrants (CRXTW) in Q3 2022, closing a stake of 39,758 shares — an estimated $3K sold.

HRT Financial first reported a position in CRXTW in Q2 2021 and held it in 5 quarters. The position peaked at $34K in Q3 2021. 5 funds tracked by Wall St. Rank hold CRXTW as of Q3 2022.

HRT Financial reported no remaining Clarus Therapeutics Holdings, Inc. Warrants position as of Q3 2022 after selling out during the quarter.
HRT Financial sold 39,758 Clarus Therapeutics Holdings, Inc. Warrants shares in Q3 2022, an estimated $3K.
HRT Financial first reported a position in Clarus Therapeutics Holdings, Inc. Warrants in Q2 2021 and held it in 5 quarters.
HRT Financial's Clarus Therapeutics Holdings, Inc. Warrants position peaked at $34K in Q3 2021.
5 funds tracked by Wall St. Rank held Clarus Therapeutics Holdings, Inc. Warrants as of Q3 2022.

Based on HRT Financial's 13F filing for Q3 2022, filed 14 Nov 2022.